Profile
Tamara Byk is Vice President of Technology Platform for Evogene Ltd.
Prior to joining Evogene, she was Head of Life Science Research for Procognia Israel Ltd.
Previously, she was a Project Leader and Deputy Senior Director of Discovery and Validation for Quark Biotech (now Quark Pharmaceuticals, Inc.) from 2000 to 2004.
She received a BSc degree in Chemistry and an MSc degree in Biochemistry from the Hebrew University.
Dr. Byk holds a PhD.
Former positions of Tamara Byk
| Companies | Position | End |
|---|---|---|
| EVOGENE LTD. | Chief Tech/Sci/R&D Officer | 2009-09-30 |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 2003-12-31 |
| SOLEGREEN | Corporate Officer/Principal | - |
Training of Tamara Byk
| The Hebrew University of Jerusalem | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| EVOGENE LTD. | Health Technology |
| SOLEGREEN | Utilities |
| Private companies | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Stock Market
- Insiders
- Tamara Byk
